Dobrin V.
- Country
- Bulgaria
- Department
- Department of cardiology
Research Overview
- Efficacy and Safety Evaluation of Sotagliflozin in Patients with Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
- ARTEMIS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction.
- ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Data & Insights
Has run more than one trial at 116 of 682 partner sites.
Specializations
Cardiovascular & Thrombotic Disorders
The investigator concentrates on acute myocardial infarction, ischemic stroke, and the broader spectrum of atherosclerotic cardiovascular disease, together with the management of deep vein thrombosis and related thrombotic events.
- Acute Myocardial Infarction
- Ischemic Stroke
- Atherosclerotic Cardiovascular Disease
- Deep Vein Thrombosis
- Major Adverse Cardiovascular Events
Therapeutic strategies prioritize inflammation‑driven risk reduction across these high‑impact conditions.
Heart Failure & Cardiomyopathy
Research activities address congestive heart failure classified as NYHA Class III, as well as both non‑ischemic cardiomyopathy and the spectrum of hypertrophic and obstructive cardiomyopathy.
- Congestive Heart Failure
- Non‑Ischemic Cardiomyopathy
- Hypertrophic Cardiomyopathy
- Obstructive Cardiomyopathy
- NYHA Class III
Efforts aim to improve functional capacity and lower hospitalization rates.
Lipid & Metabolic Disorders
The investigator’s portfolio includes disorders such as hypercholesterolemia, hypertriglyceridemia, and broader dyslipidemia, focusing on achieving LDL‑C reduction and triglyceride lowering through advanced lipid‑modifying therapies.
- Hypercholesterolemia
- Hypertriglyceridemia
- LDL‑C Reduction
- Triglyceride Lowering
- Lipid‑Modifying Therapy
Novel RNA‑based agents and monoclonal antibodies are incorporated into therapeutic development.
Renal & Hypertensive Disease
Key interests involve chronic kidney disease (including dialysis‑dependent populations), associated anemia, and persistent hypertension, especially in patients with elevated cardiovascular risk.
- Chronic Kidney Disease
- Dialysis‑Associated Anemia
- Hypertension
- High Cardiovascular Risk
- eGFR Decline
The approach links renal protection with cardiovascular outcome improvement.
Neuro‑Immune & Gastrointestinal Autoimmunity
Investigations span autoimmune conditions such as relapsing multiple sclerosis, progressive multiple sclerosis, and ulcerative colitis, emphasizing disease‑modifying and immune‑targeted therapies.
- Relapsing Multiple Sclerosis
- Progressive Multiple Sclerosis
- Ulcerative Colitis
- Immune Modulation
- Inflammatory Pathways
Therapeutic development focuses on modifying disease course and reducing inflammatory burden.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.